Journal of neurosurgery · 2008 · 65 citations · 23 references
MedicineEndocrinologySurgeryEndocrine OncologyEndocrine SurgeryHistopathologyEndocrine PathologyEndocrine Tumor DiagnosisPituitary DisordersPituitary ImagingPituitary SurgeryPituitary TumorsEndocrine Laboratory DiagnosticsPituitary InvolvementPituitary Lesion ImagingPituitary PathologyPituitary Region ImagingPituitary Tumor PathologyVon Hippel-lindau DiseaseVon Hippel-lindau Syndrome
OBJECT: Pituitary stalk hemangioblastomas are rare, and information on them is limited to a small number of case reports. To gain insight into the incidence, clinical effects, and management of pituitary stalk hemangioblastomas, the authors analyzed a series of patients with von Hippel-Lindau (VHL) disease. METHODS: Patients with VHL disease who were enrolled in a prospective National Institutes of Health natural history study were included. Clinical, imaging, and laboratory findings were analyzed. RESULTS: Two hundred fifty patients were included in the study (120 male and 130 female patients). In 8 patients (3%), 8 pituitary stalk hemangioblastomas were identified on MR imaging. This anatomical location was the most common supratentorial site for these lesions; 29% of all supratentorial hemangioblastomas were found there. The mean (+/- standard deviation) pituitary stalk hemangioblastoma volume was 0.5 +/- 0.9 cm(3) (range 0.08-2.8 cm(3)). Results of endocrine laboratory profiles were normal in all patients. All patients remained asymptomatic and none required treatment during the follow-up period (mean duration 41.4 +/- 14.4 months). CONCLUSIONS: The pituitary stalk is the most common site for the development of supratentorial hemangioblastomas in patients with VHL disease. Pituitary stalk hemangioblastomas often remain asymptomatic and do not require treatment. These findings indicate that pituitary stalk hemangioblastomas in patients with VHL disease may be managed with observation and that surgery for them can be reserved until associated signs or symptoms occur.
23
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Farida Latif, Kálmán Tory, James R. Gnarra et al. · Science · 1993 · 3K citations
Clinical Features and Natural History of von Hippel-Lindau Disease
Eamonn R. Maher, John R.W. Yates, R W J Harries et al. · QJM · 1990 · 949 citations
Hemangioblastomas of the central nervous system
Hartmut P.H. Neumann, Hans R. Eggert, K. Weigel et al. · Journal of neurosurgery · 1989 · 390 citations
Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease
T. J. Manski · JAMA · 1997 · 236 citations